Mersana Therapeutics Inc at Stifel Healthcare Conference (Virtual) Transcript
Great. Good afternoon, everyone. My name is Alex Thompson; I'm an associate here on the biotech team at Stifel. It's my pleasure to introduce Anna Protopapas, President and CEO of Mersana Therapeutics. I'm going to throw it over to her to walk through an overview of the Company. Over to you, Anna.
Thank you, Alex, and thank you for having us here today.
Moving on to slide 2. Before I start, I just want to remind you that in this presentation, I will be making forward-looking statements. At Mersana, we aspire to ADC leadership by innovating to capture the full potential of this important therapeutic modality and ultimately make a real difference in patients. ADCs are a proven therapeutic modality. We have 11 on the market and over 100 in clinical development, but there is significant opportunity for ADCs to play an even bigger role in cancer treatment, and we want to be on the leading edge of this innovation.
With Dolaflexin,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
